Published in J Virol on September 01, 1996
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol (2000) 2.21
Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol Cell Biol (2000) 1.81
The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A (2003) 1.75
Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol (2000) 1.68
Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. J Virol (1999) 1.66
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol (1998) 1.52
Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci U S A (2001) 1.49
Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J Virol (2000) 1.37
Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol (2005) 1.33
The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol (2000) 1.30
Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 1.24
Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol (2007) 1.20
Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol (2004) 1.16
PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J Virol (2001) 1.14
The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol (2000) 1.10
Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol (1999) 1.07
Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence. J Virol (2003) 1.03
The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions. J Virol (1999) 1.03
Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med (2001) 1.01
Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability. Virology (2006) 1.01
EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol (2008) 0.99
The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol (2005) 0.98
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood (2006) 0.94
Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. J Virol (2006) 0.93
Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol (2003) 0.91
An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology (2007) 0.90
C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol (2001) 0.90
Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res (2012) 0.88
Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci U S A (2009) 0.88
Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol (2008) 0.87
Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol (2006) 0.87
The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology (2008) 0.84
Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19. Blood (2011) 0.83
Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol (2007) 0.83
LMP2A does not require palmitoylation to localize to buoyant complexes or for function. J Virol (2004) 0.81
Epstein-Barr virus latent membrane protein 2A contributes to anoikis resistance through ERK activation. J Virol (2013) 0.81
Induction of therapeutic antibodies by vaccination against external loops of tumor-associated viral latent membrane protein. J Virol (2009) 0.76
Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation. J Virol (2014) 0.75
SH2 domains recognize specific phosphopeptide sequences. Cell (1993) 17.28
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
Signal transduction by lymphocyte antigen receptors. Cell (1994) 10.63
Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A (1972) 8.53
Antigen receptor tail clue. Nature (1989) 7.32
High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors. Methods Enzymol (1991) 6.25
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol (1994) 5.02
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci U S A (1995) 4.52
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J (1994) 4.23
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A (1991) 3.17
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem (1995) 3.01
Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol (1992) 2.95
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol (1991) 2.58
Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol (1994) 2.52
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A (1994) 2.38
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
Monoclonal antibodies specific for rat IgG1, IgG2a, and IgG2b subclasses, and kappa chain monotypic and allotypic determinants: reagents for use with rat monoclonal antibodies. Hybridoma (1982) 2.14
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol (1993) 1.94
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol (1991) 1.90
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol (1992) 1.74
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol (1993) 1.69
New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL) Immunol Today (1995) 1.65
The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol (1989) 1.59
Use of fluo-3 to measure cytosolic Ca2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+. Biochem J (1990) 1.56
Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol (1990) 1.56
Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells. J Virol (1991) 1.51
Nonreceptor tyrosine protein kinases. Oncogene (1993) 1.47
5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J Virol (1995) 1.26
Regulation of Epstein-Barr virus latency by latent membrane protein 2. Trends Microbiol (1996) 1.18
Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). Virology (1995) 1.18
Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes. J Virol (1990) 1.14
Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol (1995) 1.06
Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture. J Virol (1993) 1.05
Signal transduction--a conserved pathway from the membrane to the nucleus. Dev Genet (1993) 0.95
Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways. Philos Trans R Soc Lond B Biol Sci (1993) 0.95
Studies on the mechanism of desensitization of the parathyroid hormone-stimulated calcium signal in UMR-106 cells: reversal of desensitization by alkaline phosphatase but not by protein kinase C downregulation. J Bone Miner Res (1994) 0.82
Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol (1993) 0.81
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell (1999) 12.50
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med (2000) 6.57
A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell (1996) 5.97
Geometric and electronic structure/function correlations in non-heme iron enzymes. Chem Rev (2000) 5.44
Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst (1999) 4.94
SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. J Pediatr (2001) 4.82
The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res (2001) 4.08
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Clustering of genes dispensable for growth in culture in the S component of the HSV-1 genome. Science (1987) 3.45
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity (1998) 3.10
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med (2001) 3.07
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology (1988) 2.97
Expression of the G-protein--coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood (1994) 2.93
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J (1993) 2.74
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci (2000) 2.49
Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture. Proc Natl Acad Sci U S A (1987) 2.48
Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J (2001) 2.46
A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates. Gene (1984) 2.44
Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology (2008) 2.44
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A (1994) 2.38
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
Identification, properties, and gene location of a novel glycoprotein specified by herpes simplex virus 1. Virology (1986) 2.29
Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-induced membrane fusion. Virology (2001) 2.25
Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol (1998) 2.22
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Mucin-hypersecreting bile duct tumor characterized by a striking homology with an intraductal papillary mucinous tumor (IPMT) of the pancreas. Endoscopy (2000) 2.13
Magnetic resonance imaging of cerebral hemiatrophy. J Formos Med Assoc (1993) 2.10
Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis (2013) 2.09
Geographical prevalence of two types of Epstein-Barr virus. Virology (1986) 2.05
Steaming of ginseng at high temperature enhances biological activity. J Nat Prod (2000) 2.04
The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology (1997) 2.03
The roaming atom: straying from the reaction path in formaldehyde decomposition. Science (2004) 2.02
Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett (2000) 2.02
Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol (1999) 2.01
Full-length sequence, localization, and chromosomal mapping of ameloblastin. A novel tooth-specific gene. J Biol Chem (1996) 2.00
Epstein-Barr virus recombinants from overlapping cosmid fragments. J Virol (1993) 1.97
Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J Biol Chem (1998) 1.95
Subclasses of T cells with different sensitivities to cytotoxic antibody in the presence of anesthetics. Eur J Immunol (1975) 1.94
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol (1993) 1.94
Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol (2004) 1.94
Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol (1999) 1.93
Variations in intraventricular hemorrhage incidence rates among Canadian neonatal intensive care units. J Pediatr (2001) 1.92
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis (1988) 1.92
Endoscopic ultrasound-guided versus conventional transmural drainage for pancreatic pseudocysts: a prospective randomized trial. Endoscopy (2009) 1.87
Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis (2000) 1.87
Biliary papillomatosis: clinical, cholangiographic and cholangioscopic findings. Endoscopy (1998) 1.85
Endoscopic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy (2006) 1.83
Two distant clusters of partially homologous small repeats of Epstein-Barr virus are transcribed upon induction of an abortive or lytic cycle of the virus. J Virol (1983) 1.82
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med (1992) 1.80
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol (1992) 1.74
Results of transvenous embolization of cavernous dural arteriovenous fistula: a single-center experience with emphasis on complications and management. AJNR Am J Neuroradiol (2006) 1.73
Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol (1995) 1.72
Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. AJNR Am J Neuroradiol (1999) 1.70
A new strategy to predict the neoplastic polyps of the gallbladder based on a scoring system using EUS. Gastrointest Endosc (2000) 1.69
Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol (2000) 1.68
Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol (1999) 1.68
Novel critical role of a human Mediator complex for basal RNA polymerase II transcription. EMBO Rep (2001) 1.67
Hyperpolarization-activated channels HCN1 and HCN4 mediate responses to sour stimuli. Nature (2001) 1.66
Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J Virol (2000) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Improved outcome of preterm infants when delivered in tertiary care centers. Obstet Gynecol (2001) 1.63
Role for erbin in bacterial activation of Nod2. Infect Immun (2006) 1.63
Target sequences for cis-acting regulation within the dual promoter of the human c-myc gene. Mol Cell Biol (1987) 1.63
A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol (1999) 1.62
Risk adjustment for quality improvement. Pediatrics (1999) 1.61
Structure and evolution of two related transcription units of Epstein-Barr virus carrying small tandem repeats. J Virol (1985) 1.59
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol (2006) 1.55
Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators. J Biol Chem (1998) 1.53
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J (2001) 1.53
Accuracy of CT in local staging of gallbladder carcinoma. Acta Radiol (2002) 1.53
Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol (1998) 1.52
Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol (1998) 1.52
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 1.52
Demographic and therapeutic determinants of pain reactivity in very low birth weight neonates at 32 Weeks' postconceptional Age. Pediatrics (2001) 1.52
Reduced circulating angiogenic cells in Alzheimer disease. Neurology (2009) 1.52
Surgical treatment of delayed epilepsy in hemiconvulsion-hemiplegia-epilepsy syndrome. Neurology (2008) 1.51
The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology (2000) 1.49
Greater hemodynamic instability with histidine-tryptophan-ketoglutarate solution than University of Wisconsin solution during the reperfusion period in living donor liver transplantation. Transplant Proc (2008) 1.48
A cGMP-signaling pathway in a subset of olfactory sensory neurons. Proc Natl Acad Sci U S A (2000) 1.48
Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. Pharmacopsychiatry (1996) 1.48
Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity (2001) 1.47
Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood (1997) 1.45
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther (2008) 1.44